Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed data.
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data Read More »
